Ruxolitinib

Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces Autophagy and kills tumor cells through toxic Mitophagy.


Cat. No.: EX-A1670	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
500mg	750	In-stock
1g	1250	In-stock
2g	1900	In-stock
5g	3000	In-stock
10g	4800	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	INCB18424
CAS No.	941678-49-5
Purity	>98%
Formula	C17H18N6
Mol Weight	306.365
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807. [3]. Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142.
CoA	CoA of Ruxolitinib

Smiles:	N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1


		Search